21,800 Shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA) Acquired by International Assets Investment Management LLC

International Assets Investment Management LLC acquired a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 21,800 shares of the company’s stock, valued at approximately $715,000.

A number of other large investors have also recently added to or reduced their stakes in the stock. ARK Investment Management LLC boosted its position in Intellia Therapeutics by 14.7% during the fourth quarter. ARK Investment Management LLC now owns 11,412,449 shares of the company’s stock worth $347,966,000 after purchasing an additional 1,463,820 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its position in Intellia Therapeutics by 3.7% during the third quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,520,295 shares of the company’s stock worth $111,312,000 after purchasing an additional 125,639 shares during the period. Wellington Management Group LLP boosted its position in Intellia Therapeutics by 1.4% during the third quarter. Wellington Management Group LLP now owns 2,651,994 shares of the company’s stock worth $83,856,000 after purchasing an additional 36,630 shares during the period. Chevy Chase Trust Holdings LLC boosted its position in Intellia Therapeutics by 3.0% during the third quarter. Chevy Chase Trust Holdings LLC now owns 1,002,955 shares of the company’s stock worth $31,713,000 after purchasing an additional 29,412 shares during the period. Finally, Rhenman & Partners Asset Management AB boosted its position in Intellia Therapeutics by 1,600.0% during the third quarter. Rhenman & Partners Asset Management AB now owns 850,000 shares of the company’s stock worth $26,877,000 after purchasing an additional 800,000 shares during the period. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Price Performance

Shares of NTLA stock opened at $21.17 on Thursday. The stock has a market cap of $2.04 billion, a P/E ratio of -3.91 and a beta of 1.77. Intellia Therapeutics, Inc. has a one year low of $20.78 and a one year high of $47.48. The stock has a fifty day moving average price of $26.81 and a 200 day moving average price of $27.68.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, February 22nd. The company reported ($1.46) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.01. The firm had revenue of ($1.92) million during the quarter, compared to analysts’ expectations of $15.10 million. Intellia Therapeutics had a negative return on equity of 43.91% and a negative net margin of 893.34%. During the same period last year, the business earned ($1.40) earnings per share. Equities research analysts anticipate that Intellia Therapeutics, Inc. will post -5.58 EPS for the current year.

Insider Buying and Selling

In related news, EVP James Basta sold 2,297 shares of the firm’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $32.99, for a total value of $75,778.03. Following the completion of the transaction, the executive vice president now directly owns 81,571 shares of the company’s stock, valued at $2,691,027.29. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 3.00% of the stock is owned by company insiders.

Analysts Set New Price Targets

NTLA has been the subject of a number of recent analyst reports. Wedbush reaffirmed a “neutral” rating and set a $29.00 target price on shares of Intellia Therapeutics in a research report on Tuesday. The Goldman Sachs Group cut Intellia Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $136.00 to $32.00 in a research report on Friday, February 23rd. Wolfe Research assumed coverage on Intellia Therapeutics in a research report on Thursday, February 15th. They issued a “peer perform” rating for the company. Finally, Canaccord Genuity Group increased their price objective on Intellia Therapeutics from $72.00 to $73.00 and gave the company a “buy” rating in a research report on Friday, February 23rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $67.00.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.